Table 2.
Positive rate of immunohistochemical markers in primary and metastatic sites
| Marker | Total (%) (n = 93) | Colon cancer (%) (n = 45) | Breast cancer (%) (n = 9) | Head and neck cancer (%) (n = 8) | Genital cancer (%) (n = 11) | Soft‐tissue sarcoma (%) (n = 14) | Other cancer (%) (n = 6) |
|---|---|---|---|---|---|---|---|
| LAT1 | |||||||
| Primary site | 40 | 35 | 56 | 75 | 45 | 21 | 33 |
| (37/93) | (16/45) | (5/9) | (6/8) | (5/11) | (3/14) | (2/6) | |
| Metastatic site | 65 | 60 | 78 | 88 | 91 | 43 | 50 |
| (60/93) | (27/45) | (7/9) | (7/8) | (10/11) | (6/14) | (3/6) | |
| CD98 | |||||||
| Primary site | 24 | 22 | 11 | 63 | 36 | 0 | 17 |
| (22/93) | (10/45) | (1/9) | (5/8) | (4/11) | (0/14) | (1/6) | |
| Metastatic site | 45 | 46 | 11 | 88 | 27 | 21 | 50 |
| (42/93) | (21/45) | (1/9) | (7/8) | (3/11) | (3/14) | (3/6) | |
| Ki‐67 | |||||||
| Primary site | 56 | 51 | 56 | 63 | 36 | 29 | 50 |
| (52/93) | (23/45) | (5/9) | (5/8) | (4/11) | (4/14) | (3/6) | |
| Metastatic site | 84 | 84 | 89 | 88 | 82 | 86 | 67 |
| (78/93) | (38/45) | (8/9) | (7/8) | (9/11) | (12/14) | (4/6) | |
| VEGF | |||||||
| Primary site | 41 | 29 | 67 | 50 | 36 | 36 | 50 |
| (35/93) | (13/45) | (6/9) | (4/8) | (4/11) | (5/14) | (3/6) | |
| Metastatic site | 67 | 51 | 78 | 75 | 91 | 86 | 67 |
| (62/93) | (23/45) | (7/9) | (6/8) | (10/11) | (12/14) | (4/6) | |
| CD31 | |||||||
| Primary site | 45 | 31 | 56 | 75 | 64 | 50 | 50 |
| (42/93) | (14/45) | (5/9) | (6/8) | (7/11) | (7/14) | (3/6) | |
| Metastatic site | 73 | 51 | 89 | 100 | 91 | 93 | 100 |
| (68/93) | (23/45) | (8/9) | (8/8) | (10/11) | (13/14) | (6/6) | |
| CD34 | |||||||
| Primary site | 39 | 20 | 67 | 63 | 36 | 57 | 50 |
| (36/93) | (9/45) | (6/9) | (5/8) | (4/11) | (8/14) | (3/6) | |
| Metastatic site | 61 | 38 | 89 | 75 | 73 | 86 | 100 |
| (57/93) | (17/45) | (8/9) | (6/8) | (8/11) | (12/14) | (6/6) | |
LAT, l‐type amino acid transporter; NS, not significant; VEGF, vascular endothelial growth factor.